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Abstract 
We explored socioeconomic and demographic disparities in breast cancer (BC) stage at 
presentation and survival in a Swiss population-based sample of female BC patients linked to the 
census-based Swiss National Cohort. Tumour stage was classified according to Surveillance, 
Epidemiology and End Results (SEER) Program summary stage (in situ/localized/regional/distant). 
We used highest education level attained to estimate SEP (low/middle/high). Further 
demographic characteristics of interest were age at presentation (30-49/50-69/70-84 years), 
living in a canton with organized screening (yes/no), urbanity of residence (urban/peri-
urban/rural), civil status (single/married/widowed/divorced) and nationality (Swiss/non-Swiss). 
We used ordered logistic regression models to analyse factors associated with BC stage at 
presentation and competing risk regression models for factors associated with survival. Odds of 
later-stage BC were significantly increased for low SEP women (odds ratio (OR) 1.19, 95%CI 1.06-
1.34) compared to women of high SEP. Further, women living in a canton without organized 
screening programme, women diagnosed outside the targeted screening age and 
single/widowed/divorced women were more often diagnosed at later stages. Women of low SEP 
experienced an increased risk of dying from BC (sub-hazard ratio 1.22, 95%CI 1.05-1.43) 
compared to women of high SEP. Notably, these survival inequalities could not be explained by 
socioeconomic differences in stage at presentation and/or other sociodemographic factors. It is 
concerning that these social gradients have been observed in a country with universal health 
insurance coverage, high health expenditures and one of the highest life expectancies in the 
world. 
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Background 1 
Breast cancer (BC) is the most common cancer in Swiss women. In Switzerland, each year 2 
approximately 5,700 women are newly diagnosed with BC and the lifetime risk of developing BC 3 
is almost 13%.1 Although mortality has fallen consistently over the last 30 years, BC is the leading 4 
cause of cancer death in Swiss women with approximately 1,400 women dying each year of this 5 
disease.1 Tumour stage at presentation remains one of the major prognostics factors and women 6 
with early-stage BC are expected to have excellent survival rates. In a recent Swiss study, age-7 
standardized 10-year relative survival varied from 9.3% (Stage IV) to 94.5% (Stage I) depending 8 
on stage at presentation.2  9 
Several studies outside of Switzerland have reported negative associations between 10 
socioeconomic position (SEP) and BC stage at presentation as well as socioeconomic inequalities 11 
in survival after BC diagnosis.3 Socioeconomic and demographic factors may influence access to 12 
health care4, cancer awareness5 and woman’s attitudes towards preventive methods such as 13 
mammography screening, clinical breast examination and breast self-examination.6  14 
In Switzerland, health care is organized at the cantonal level, resulting in regional differences in 15 
provision of cancer prevention and management services.7 A Swiss BC pattern of care study, for 16 
example, reported considerable regional variations in early BC detection and treatment.7 In 17 
western Switzerland (French-speaking part of the country), organized BC screening programmes 18 
have gradually been implemented since 1999 for women aged 50 to 69 years, whereas in most 19 
other regions (German and Italian-speaking parts of Switzerland) only opportunistic screening is 20 
available.8 Consequently, screening uptake varies by canton and region. The Swiss Health Survey 21 
2012 reports that in 2010-2011, cantons with organized mammography screening had a 68% 22 
mammogram coverage of women in the recommended screening age (50-69 years), compared 23 
to 37% in cantons without an organized programme.9 Organized BC screening may reduce social 24 
inequalities in screening uptake10, 11, although this has not been consistently observed across 25 
countries.12 26 
Several studies have identified stage at presentation as an important factor in survival 27 
differences between socioeconomic groups.13 In most studies, however, disparities remained 28 
after adjustment for stage and other tumour and demographic characteristics.13 Remaining 29 
disparities have been associated with treatment disparities, variations in comorbidities and/or 30 
additional factors like variations in psychosocial well-being and patients’ support.13 In Geneva, 31 
women with lower SEP were diagnosed with more advanced BC, received more often suboptimal 32 
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treatment and showed lower cause-specific and overall survival.14 A later study in Geneva, 33 
observed substantial social inequalities in BC management including diagnostic procedures and 34 
primary treatment.15 35 
A major goal of health care systems is to equally improve the health in all groups of the 36 
population they serve.16 Despite this aim, socioeconomic and -demographic health inequalities in 37 
BC detection and survival have been observed all over the world13, including countries with tax-38 
funded health care systems designed to provide equal access to care.17, 18 39 
Swiss data on socioeconomic health inequalities in stage at presentation and survival of BC in 40 
women is very limited. Therefore, the present study aimed to evaluate socioeconomic and 41 
demographic disparities in BC stage at presentation and survival in a Swiss population-based 42 
sample of female BC patients diagnosed between 2001 and 2008.  43 
Materials and Methods 44 
Data sources and inclusion criteria 45 
This study is based on data from the SNC-NICER Cancer Epidemiology Study. The SNC-NICER 46 
Cancer Epidemiology Study took advantage of the Swiss National Cohort (SNC) and the National 47 
Institute for Cancer Epidemiology and Registration (NICER) cancer registry network to build a 48 
comprehensive historical cohort, allowing epidemiologic analysis of factors associated with 49 
cancer incidence, mortality and survival in Switzerland.  50 
A detailed description of the SNC can be found elsewhere.19 Briefly, 1990 and 2000 census 51 
records were probabilistically linked to cause-specific mortality or emigration records from 1991-52 
2013 provided by the Federal Statistical Office (FSO). The Swiss census is mandatory and virtually 53 
complete with a 2000 census estimated coverage of 98.6%.19 This study used SNC 54 
sociodemographic information on sex, education level, marital status, place of residence and 55 
nationality at census date. The coding of the underlying cause of death is federally standardised 56 
by the FSO. Since 1995, the 10th revision of the international classification of diseases and related 57 
health problems (ICD-10) has been used following international standards.  58 
In Switzerland, cancer registration is primarily organized at the cantonal level. The earliest cancer 59 
registry (CR) data is available from Geneva dating back to 1970, followed by Vaud and Neuchâtel 60 
(1974), Zurich (1980), St. Gallen-Appenzell (1980), Basel-Stadt and Basel-Landschaft (1981), 61 
Valais (1989), Graubünden (1989), Glarus (1992), Ticino (1996), Jura (2005) and Fribourg (2006). 62 
More recently, cancer registration has been introduced in Lucerne (2010), Nidwalden, 63 
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Obwalden, Uri, Zug (2011), Thurgau (2012), Aargau (2013) and Bern (2014). All CRs implemented 64 
before 2008 have been requested to participate in the SNC-NICER Cancer Epidemiology Study. 65 
Seven out of eleven CRs eligible for the study, agreed to participate and provided incidence data 66 
to the pooled dataset: Fribourg, Geneva, Neuchâtel, Ticino, Valais, Vaud and Zurich. Data from 67 
these CRs were probabilistically linked to the SNC, including all incident cases starting from the 68 
date of the census 1990 (or from the implementation of cantonal cancer registration if later) 69 
through the end of 2008. In 2008, these cantons covered 46.1% of the Swiss population. To 70 
assess sample representativeness, we compared frequency distributions (age, civil status, 71 
education, urbanity of residence and nationality) between female residents of participating 72 
cantons and whole of Switzerland using census 2000 information. Compared to total 73 
Switzerland, the participating cantons showed distinctly higher proportions of women with 74 
tertiary education (16.8% versus 11.1%), women living in urban and peri-urban areas (35.3% 75 
versus 24.7% and 48.8% versus 41.2%, respectively), and women with foreign nationality (22.7% 76 
vs.15.5%). Cancer registration data used in this study included sex, date of birth, date of cancer 77 
diagnosis, basis of diagnosis, topography, morphology and behaviour of the tumour, and 78 
Tumour, Node and Metastasis staging information (TNM).  79 
The current study population included 17,298 female BC cases (carcinoma in situ and invasive 80 
BC) first diagnosed between Census 2000 (5th of December 2000) and 31st of December 2008. 81 
TNM codes were based on the fifth and sixth TNM editions. The Census 2000 was used as 82 
starting point as for previous time periods, the proportion of missing stage information was high 83 
(up to >25%) in two cantons. Education was used as a proxy for SEP so young women (< 30 years 84 
of age at diagnosis, N=46) and women with missing education information (N=147) were 85 
excluded from the study population. In addition, women diagnosed at 85 years of age or older 86 
were excluded (N=936) because data quality (percentage of death certificate only cases [%DCO] 87 
8.2%, histologically verified cases 78.4%) and completeness of stage information (60.1%) was low 88 
in this age group. The study population showed %DCO of 0.4% indicating high completeness of 89 
case ascertainment with 98.3% of the cases histologically verified and 94.8% with sufficient TNM 90 
information to classify tumour stage.  91 
Stage at presentation analyses were based on data from a subset of cantonal cancer registries 92 
(Geneva, Valais, Zurich) that provided breast carcinoma in situ cases (N=10,915). In a 93 
supplemental analysis, stage at presentation calculations were repeated and limited to invasive 94 
BCs to enable the inclusion of all participating cancer registries (Suppl. Table 1). The 95 
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supplemental analysis followed survival analyses were based on invasive cancers including all 96 
participating cancer registries (16,296). 97 
Analytic methods 98 
Surveillance, Epidemiology and End Results (SEER) Program summary stage was calculated based 99 
on the TNM classification system following the algorithm for mapping stage at diagnosis from 100 
TNM to SEER summary stage as described by Walters et al.20 We used SEER summary stage 101 
instead of the more detailed TNM staging system due to extensive and significant revision in BC 102 
staging between the fifth and sixth TNM edition.  103 
We prioritized pathological T and N over clinical T and N. Missing M or Mx were assumed to be 104 
equivalent to M0. If clinical and pathological M was available, any indication of metastasis was 105 
prioritized. Pathological and clinical T and N information was available in 84.1% and 46.0% of all 106 
invasive BC cases, respectively. The proportion of cases with missing M or Mx was 26.4%. 107 
Overall, tumour stage could be calculated for 94.9% of all invasive BC cases. Carcinoma in situ 108 
cases have been identified based on the ICD-O-3 behaviour code.  109 
We used highest education level attained by the woman to estimate SEP (compulsory education 110 
or less: low SEP, secondary education: middle SEP, tertiary education: high SEP).  111 
We descriptively investigated stage at presentation by SEP, age-group (30-49, 50-69, 70-84 112 
years) and residence (canton with or without organized screening). Ordered logistic regression 113 
models examined the association between cancer stage at presentation and SEP. We calculated 114 
three models using the following variables as predictors for stage at presentation: (model 1) SEP; 115 
(model 2) model 1 plus age at presentation (30-49, 50-69, 70-84 years), civil status (30-49, 50-69, 116 
70-84 years) and nationality (Swiss, non-Swiss); (model 3) model 2 plus urbanity of residence and 117 
canton with or without organized screening programme. The third model has been additionally 118 
adjusted for canton of residence. No significant interactions were observed, therefore, we only 119 
included main effects in the final model.  120 
For women within the recommended screening age, we conducted a sub-analysis of Valais and 121 
Geneva, the only two cantons which both, offered organized screening during the study period 122 
and provided carcinoma in situ cases to the study population. We examined the association 123 
between being diagnosed within or outside the organized programme and SEP using logistic 124 
regression including civil status and nationality and canton of residence as covariates. 125 
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Survival was analysed using competing risk regressions based on Fine and Gray's proportional 126 
hazard model.21 All underlying causes of death other than BC were classified as competing risks. 127 
Four models have been calculated using the following variables as predictors: (model 1) SEP; 128 
(model 2) model 1 plus age at presentation, civil status and nationality; (model 3) model 2 plus 129 
stage at presentation; and (model 4) model 3 plus urbanity of residenc and canton with or 130 
without organized screening programme. Results of survival analyses are reported as sub-hazard 131 
ratios of death due to BC (SHRs) with 95% confidence intervals (95%CI).  132 
Both final models (stage at presentation and survival analyses) have been additionally adjusted 133 
for canton of residence to account for unmeasured canton characteristics associated with SEP 134 
distribution and stage at diagnosis/survival.   135 
All analyses were performed using the statistical software package Stata, version 13.1 for 136 
Windows (StataCorp, College Station, Texas). 137 
Results 138 
Patient characteristics by SEP cases included in stage at presentation and survival analyses are 139 
listed in Table 1. Incident breast carcinoma cases (Ntotal=10,915, Nstaged=10,362) by cancer 140 
registry included in stage at presentation analyses is shown in Suppl. Table 2. Incident BC cases 141 
(Ntotal=16,296; Nstaged=15,462) and person-years (PY) (PYstotal=127,040; PYstaged=121,553) by 142 
cancer registry included in survival analyses is shown in Suppl. Table 3.  143 
BC stage at presentation 144 
In the unadjusted model, odds ratios (ORs) of later stage at BC diagnosis were significantly 145 
increased for women of middle (OR 1.18, 95%CI 1.07-1.31) and low SEP (OR 1.30, 95%CI 1.16-146 
1.46) compared to women of high SEP (Table 2). After adjustment for demographic factors 147 
(model 2) and area of living (urbanity of residence, canton with/without organized screening, 148 
canton of living) (model 3), ORs for middle SEP women and low SEP women decreased to 1.09 149 
(95%CI 0.99-1.21) and 1.19 (95%CI 1.06-1.34), respectively. In the final model, women living in a 150 
canton without an organized screening programme were also more likely to have their BC 151 
diagnosed at a later stage (OR 1.42, 95%CI 1.30-1.55). Further, women outside the targeted 152 
screening age (30-49 years: OR 1.22, 95%CI 1.11-1.33; 70-84 years OR: 1.31, 95%CI 1.19-1.45) 153 
and single/widowed/divorced women showed elevated risks for later stages at diagnosis (OR 154 
1.12 (95%CI 0.99-1.27) - 1.14 (95%CI 1.02-1.27)).  155 
8 
 
We observed higher proportions of early stage BC (carcinoma in situ and localized cancers) in 156 
cantons with organized BC screening compared to the canton without organized screening 157 
(Figure 1). In the recommended screening age-group (50-69 years), the observed proportion of 158 
early stage BC (carcinoma in situ and localized BC) was 64.7% vs. 51.9% (low SEP), 65.0% vs. 159 
57.0% (middle SEP), and 69.4% vs. 56.6% (high SEP). A similar tendency towards higher 160 
proportions of early stage BC in cantons with organized screening (regardless of SEP) was also 161 
observed in the age-group 70-84 years. However, due to comparably high number of cases 162 
without stage information, i.e. in the canton without organized screening, figures for this age-163 
group are difficult to interpret. In women aged 30-49 years, early stage detection in women 164 
varied across SEPs between 56.9% (middle SEP) and 59.5% (high SEP) in cantons with organized 165 
screening and 50.0% (middle SEP) and 53.3% (high SEP) in the canton without organized 166 
screening. 167 
When looking at carcinoma in situ cases in women in the recommended screening age-group, 168 
only women living in a canton with organized screening programme showed a social gradient 169 
with 9.3%, 11.9% and 15.0% of carcinoma in situ cases for low, middle and high SEP women, 170 
respectively. In the canton without organized screening, the proportion of carcinoma in situ 171 
cases were fairly stable with 8.5% (low SEP), 9.8% (middle SEP) and 8.2% (high SEP).In cantons 172 
with organized programmes, 16% (canton Geneva) and 32% (canton Valais) of diagnosed BC 173 
cases in the age-group eligible for organized BC screening were detected within the framework 174 
of an organized programme. Compared to women with high SEP, women with middle (OR 1.25, 175 
95%CI 1.03-1.53) and low SEP (OR 1.39, 95%CI 1.11-1.73) were more likely to be diagnosed 176 
outside of the organized screening programme.  177 
BC survival 178 
Stage information was lacking in 5.1% (Table 1). Of the 16,296 incident cases included in the 179 
survival analyses, 3,713 cases died before the end of follow-up (22.8%) and 229 (1.4%) were lost-180 
to-follow-up.  181 
In all models, diagnosed women with low SEP were more likely to die of BC compared to women 182 
with high SEP (Table 3). SHRs of low SEP women gradually decreased from 1.60 (95%CI 1.40-1.83, 183 
model 1) to 1.22 (95% CI 1.05-1.43, model 4) after adjustment for further demographic factors 184 
(model 2), stage at presentation (model 3) and area of living (canton with/without organized 185 
screening, canton of living, model 4). In the fully adjusted model (model 4), later stage at 186 
presentation was strongly associated with an increased risk of BC death (regional stage: SHR 187 
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4.12, 95%CI 3.66-4.63; distant stage: SHR 27.27, 95%CI 23.67-31.41). Compared to women 188 
diagnosed in the recommended screening age (50-69 years), women aged 70-84 years showed 189 
an elevated risk of BC death (SHR 1.34, 95%CI 1.19-1.50). For women aged 30-49 years, a 190 
reduced risk was observed (SHR 0.76, 95%CI 0.66-0.86). Living in a canton without an organized 191 
screening was associated with an increased SHR (SHR 1.44, 95%CI 1.23-1.68) even after 192 
adjustment for stage at diagnosis. Further, living in a non-urban region was associated with an 193 
increased risk of BC death with SHRs of 1.13 (95%CI 1.02-1.26) (peri-urban region) and 1.21 194 
(95%CI 1.03-1.41) (rural region). Residents of foreign nationality were at lower risk of dying from 195 
their BC (SHR 0.84, 95%CI 0.73-0.98). We observed no statistically significant effects for civil 196 
status in the fully adjusted model (Table 3).  197 
Discussion 198 
Summary of main findings 199 
Despite universal health insurance coverage22, high health expenditures22, the highest average 200 
household net financial wealth worldwide23 and one of the highest life expectancies in the 201 
world24, high risk groups for later-stage BC and lower BC survival were identified in Switzerland. 202 
In our study, women of lower SEP, unmarried women, women below (<50 years) or above (>69 203 
years) the recommended screening age, and women living in a canton with no organized BC 204 
screening programme showed an increased risk of being diagnosed with a later-stage BC. In 205 
addition, women of lower SEP experienced poorer disease-specific survival. Notably, these 206 
survival inequalities could not be explained by socioeconomic differences in stage at 207 
presentation and/or other sociodemographic factors such as age, nationality and civil status. 208 
Discussion in the context of the literature 209 
Our Swiss results are in line with international data, showing that lower SEP is associated with 210 
later-stage BC and shortened survival.3 Much of the deprivation gap in survival can be attributed 211 
to inequalities in stage at presentation, the most important single predictor for BC survival.13, 25 212 
However, in most research socioeconomic survival gaps remained in stage-stratified analyses or 213 
after adjustment for stage at diagnosis.13, 25 Further, socioeconomic inequalities for BC stage and 214 
survival were observed in various countries irrespective of the measurement used for SEP 215 
classification (e.g. education, occupation, income, area-based deprivation index).13 Possible 216 
reasons for the delayed BC diagnosis in lower SEP women might be related to inequalities in 217 
health care access4, cancer awareness5 and/or attitudes towards cancer (e. g. cancer fatalism).6 218 
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All these factors might substantially contribute to observed disparities in BC screening uptake11, 219 
26, and/or cancer-related health behaviour such as health care seeking after detection of first 220 
symptoms (patient-mediated delay).27 Essentially, equal access to health care goes beyond 221 
universal health insurance coverage and adequate provision of accessible health services (such 222 
as provision in proximity of the patient's residence).28 Additional factors such as language 223 
barriers, uncovered costs (travel costs, childcare during consultation/treatment) or previous 224 
negative health care experiences might hamper health care access of individuals and specific 225 
social groups.29 Disparities in cancer awareness might have also influenced the results. In a 226 
Danish study, for example, lower SEP was associated with less awareness of BC symptoms and 227 
risk factors.5 Further, fatalistic attitudes towards cancer have been shown to be associated with 228 
lower SEP6, 30, whereas cancer fatalism in turn was associated with being less positive about early 229 
detection and being more fearful about seeking help for suspicious symptoms.30 In our study, we 230 
observed a social shift towards higher proportions of carcinoma in situ cases for women in the 231 
recommended screening age only in cantons offering organized screening. In the canton without 232 
organized screening, proportions of carcinoma in situ cases were fairly equal across SEP groups, 233 
similar to those observed in low SEP women in cantons with organized screening. As carcinoma 234 
in situ are rare in the symptomatic setting, observed variations were most likely caused by 235 
differences in mammography screening use (organized and/or opportunistic). In the canton 236 
without organized screening programme, social inequalities in early detection were mainly 237 
visible for localized BC indicating that in this canton other factors such as inequalities in cancer 238 
awareness/knowledge, health care access and /or help seeking behaviour after detection of 239 
symptoms might have led to the observed results.  240 
In our study, socioeconomic inequalities in survival remained after adjusting for stage at 241 
presentation suggesting that further factors such as treatment disparities and/or variations in 242 
comorbidities might play a role. This assumption is supported by the findings in the canton of 243 
Geneva, where lower SEP women were more likely to receive suboptimal treatment compared 244 
to their more affluent counterparts.14, 15  245 
In women aged 70-84 years, lower SEP was associated with an increased proportion of unstaged 246 
BCs. However, a clear social gradient was only apparent in the cantons with organized screening 247 
programmes. Women 85 years and older were excluded from the analyses because of the high 248 
proportion with missing stage information despite the fact that tumour stage should be 249 
investigated (at least clinically) in all women with BC.31 However, a distinction must be made 250 
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between a true lack of stage information and a lack of reporting stage.32 A true lack of staging 251 
might occur in patients with very limited life expectancy (severe comorbidities, high age)32, 33 or 252 
due to patients’ choice.32, 34 In contrast, lack of reporting refers to cases where clinical and/or 253 
pathological stage has been investigated but has not been captured by the cancer registry. A 254 
study investigating the completeness of BC staging in the New Zealand Cancer Registry, found 255 
that 12% of staged BC cases were recorded as unknown stage in the cancer registry system.32 256 
Although observed socioeconomic inequalities in diagnostic assessment might be – at least 257 
partly – explained by the fact that comorbidities are more common in lower SEP women and in 258 
older women.35  259 
Biennial mammography coverage in the recommended screening age was substantially higher in 260 
cantons with an organized programme (located in the western, French-speaking region of 261 
Switzerland) compared to cantons without organized programme.9 However, the participation 262 
rate in the organized programmes varied substantially across cantons. In 2004, screening 263 
coverage in the organized programme of women aged 50-69 years was 23% in Geneva compared 264 
to 66% in Valais.36 Importantly, opportunistic screening has widely been offered concomitantly 265 
to organized programmes in Switzerland.36 A prospective study in Geneva reported that only 266 
12% of women invited to screening were screened within the organized programme and 39% 267 
received screening outside of the framework of the organized programme.10 Therefore, the 268 
lower participation rate in the Geneva programme likely reﬂects a higher prevalence of 269 
opportunistic screening rather than real differences in mammography coverage.37  270 
In our analyses, the cantons with organized BC screening programmes showed a shift towards 271 
earlier stages in women aged 50 years and older compared to the canton without an 272 
implemented programme. A similar shift – albeit less pronounced – has been observed for 273 
younger women below the recommended screening age indicating that younger women in 274 
cantons with organised screening are more likely to undergo mammography screening than their 275 
counterparts in cantons without a programme.  276 
Women outside the recommended screening age showed an increased risk of being diagnosed 277 
at later stages. For the time period under investigation, the recommended screening age in 278 
Switzerland was 50-69 years. The age-cut was based on the fact that at this time the most 279 
convincing evidence for a beneficial effect available from randomized controlled trials existed for 280 
women aged 50-69 years. However, women older than 69 years were allowed to continue 281 
screening within the organized program if desired and if no major comorbidities existed.36 282 
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Diagnosing BC by mammography is more difficult in younger women because their breast tissue 283 
is denser making it hard to detect anomalies - the main reason why mammography screening is 284 
not recommended for younger women.36 BC in younger women has been shown to be more 285 
aggressive38 and have a less favourable prognosis39, although the latter has not been consistently 286 
observed.40 In our study, we observed an increased survival for women below the age of 50 287 
years compared to their older counterparts (overall and adjusted for stage at presentation). An 288 
earlier Swiss study found that women with BC diagnosed below the age of 40 years had 289 
substantially lower survival than women diagnosed between the age of 40-49 years.39 Due to the 290 
small number of cases below the age of 40 years we categorised younger women as < 50 years 291 
thus potential survival disadvantages in the very young women could not be examined in this 292 
study.  293 
Several studies outside of Switzerland observed beneficial impacts of being married in regard to 294 
BC stage at presentation and survival after BC13, 41, indicating that social support might have a 295 
significant impact on cancer detection, treatment and survival.41 A study in the United States 296 
observed that unmarried women were at higher risk of being diagnosed with metastatic cancer, 297 
under-treatment and death resulting from their cancer.41 In our study, we observed an increased 298 
risk for unmarried women for being diagnosed with later stage BC (albeit not reaching 299 
significance for widowed women). For survival after BC, we observed a significantly lower 300 
survival only in single women and only if not adjusted for stage at diagnosis. In this study marital 301 
status was obtained from the census and with increasing time between date of census and end 302 
of follow-up, marital status might have changed leading to misclassification when referring to 303 
the time of or after diagnosis.  304 
In our study, women living in non-urban regions showed lower survival compared to their urban 305 
counterparts. Factors that may mediate these disparities may include inequalities in tumour 306 
characteristics (i.e. stage at presentation), patients’ treatment preferences and adherence, 307 
and/or access to and quality of care received. However, in our study we did not observe 308 
significant disparities in stage at presentation between the rural and urban population 309 
suggesting that differences in early-detection played a minor role.  310 
Compared to women with Swiss nationality, our results suggest that women of foreign 311 
nationality have an overall and stage-specific survival benefit. A potential explanation for these 312 
differences is the so-called “healthy migrant effect”. The healthy migrant effect describes an 313 
empirically observed mortality advantage of migrants relative to the population in the host 314 
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country due to self-selection of migrants who tend to differ from their fellow countrymen in 315 
respect to education, risk exposure or health, leading to better health outcomes despite 316 
potential social inequalities and discrimination in the host country. However, data quality issues 317 
might have affected the results in this study. Death records of non-Swiss residents showed an 318 
increased probability of not being linked to census data compared to death records of Swiss 319 
nationals19 and (undocumented) out-migration may have led to incomplete mortality follow-up, 320 
especially in semi-skilled or unskilled migrant workers, who tend to leave the home country 321 
when they are sick or disabled.42 Additionally, it is difficult to draw conclusions for the non-Swiss 322 
population because it is a highly heterogeneous group. Non-Swiss have different countries of 323 
origin, migration status (first, second or third generation immigrants), type of residence permit, 324 
level of education, employment and income, to name a few. Hence, this topic should be 325 
investigated further in future studies.  326 
Strengths and Limitations 327 
This is the first Swiss study investigating socioeconomic inequalities of BC stage at presentation 328 
and survival, combining data from multiple Swiss cantons and from a national census. Overall, 329 
the study population had less than 0.5% DCO cases indicating a high completeness of case 330 
ascertainment. In the age-group under investigation, stage information was available for 95% of 331 
all cases. 332 
Our study has some limitations.  First,  the meaning and consequences of educational attainment 333 
might vary by birth cohort.43 However, there is considerable international evidence that 334 
education is strongly associated with health, health behaviour and preventive service use and 335 
that a substantial share of these effects are of causal origin.44 In addition, individual education is 336 
generally stable beyond early adulthood whereas civil status and living conditions are more likely 337 
to change over time and individual education level was virtually complete (>99%) in the study 338 
population. In a preceeding analysis, we compared three indicators of SEP in relation to stage at 339 
presentation: (1) education woman - highest education level attained by the woman 340 
(compulsory or less, upper-secondary, upper-tertiary education), (2) education couple – if 341 
married, highest education level attained by the woman or spouse, and (3) quintiles of the Swiss 342 
neighbourhood index (Swiss-SEP), a composite area-level SEP measure based on income, 343 
education, occupation and housing conditions.45 Regardless of SEP indicator used, we observed 344 
comparable patterns and effects for SEP and the covariates included in the models46, although 345 
importantly, each indicator of SEP measures different aspects of socioeconomic stratification.43 346 
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Overall, only 7 out of 26 Swiss cantons participated in the study covering around 46% of the 347 
population. Further, stage at presentation analyses were restricted to cantonal cancer registries 348 
providing carcinoma in situ cases diminishing population coverage for these analyses to 27%. The 349 
resulting study sample was not representative for the female Swiss population with respect to 350 
SEP, urbanity or residence and nationality. Importantly, there may be also other unmeasured 351 
cantonal/regional characteristics associated with stage at presentation and/or survival that could 352 
impact the results. Therefore, we additionally adjusted for canton of residence in the final 353 
models. Generalisability of these finding, although better than previous publications, remains 354 
limited by the lack of cantonal cancer registry participation and should be made with caution. 355 
Another weakness of the study is the lack of more detailed tumour characteristics ((morphologic 356 
subtype, grade, oestrogen receptor (ER) status, progesterone-receptor (PR) status, human 357 
epidermal growth factor receptor 2 (HER2/neu) and other prognostic factors such as 358 
comorbidities and cancer treatment. From studies outside of Switzerland, it is known that 359 
morphological type of BC and ER status might vary between social groups.13 A Swiss study 360 
conducted in Geneva reported variations depending on SEP for stage at presentation and 361 
morphological BC type, but not for grade, tumour size and ER status.14 Substantial treatment 362 
differences between social groups have been also been reported for this canton.14, 15 Additional 363 
analysis of morphological type by SEP (not presented) suggests that morphological differences 364 
reported from Geneva might be largely the result of varying proportions of cases with unknown 365 
morphological type (classified as other morphological type in their analyses) rather than 366 
reflecting real morphological differences between social groups. Further, stage at presentation 367 
has been consistently shown to be a major predictor of BC survival and other tumour 368 
characteristics contributed much less to the explanation of the observed survival experience.13  369 
Comorbidities are more common in lower SEP women and may have an adverse impact on 370 
cancer survival.35 Comorbidities might be associated with less complete diagnostic assessment 371 
including biopsy for staging32, 33, limited treatment options, and a decreased likelihood to receive 372 
treatment with curative intent47. Further, SEP might influence patients treatment choice48 373 
and/or adherence to treatment49. However, studies in the canton of Geneva suggest that 374 
observed survival inequalities after BC are – at least partly – caused by differences in care 375 
management depending on SEP.14, 15 Unfortunately, information on comorbidities were not 376 
available for this study.  377 
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Since the introduction of BC screening programmes, the usefulness of mammography screening 378 
has been questioned. Critics argue that screening-induced over-diagnosis and its consequences 379 
outbalance potential mortality benefits.50 Consequently, our analyses might be affected by 380 
higher proportions of over-diagnosis in the cantons with implemented screening programme 381 
resulting in higher mammography screening coverage. 382 
Finally, we used the SEER basic summary staging because substantial TNM classification changes 383 
over the investigated time period prevented the use of the more detailed TNM-staging. A more 384 
detailed staging system might have shown stronger effects. 385 
Conclusions 386 
Characteristics associated with later stage BC diagnosis in Switzerland were lower SEP, being 387 
unmarried, being outside of the recommended screening age and living in a canton without an 388 
organized BC screening programme. In addition, women of lower SEP experienced poorer 389 
disease-specific survival. Notably, these survival inequalities could not be explained by 390 
socioeconomic differences at stage of presentation and/or other sociodemographic factors such 391 
as age, nationality and civil status. Appropriate intervention strategies are needed to reduce 392 
socioeconomic and demographic health inequalities in women with BC. 393 
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Table 1: Patient characteristics by socioeconomic position (SEP). (1) Carcinoma in situ and invasive breast 
cancer cases from three Swiss cancer registries (CRs) for stage at presentation analyses. (2) Invasive 
breast cancer cases from seven Swiss cancer registries (CRs) for survival analyses. 
Analysis of SEP and 
stage at presentation 
Low SEP    Middle SEP High SEP Total 
N column %          N column %          N column %       N column %          
(1) Stage at presentation analyses (N=10,915)     
Stage at presentation 
in situ 217 7.3 574 9.6 211 11.0 1,002 9.2 
Local 1,382 46.3 2,780 46.3 951 49.4 5,113 46.8 
Regional 1,036 34.7 2,139 35.6 625 32.5 3,800 34.8 
distant 142 4.8 239 4.0 66 3.4 447 4.1 
unknown stage 206 6.9 275 4.6 72 3.7 553 5.1 
Age at presentation 
<50 years 435 14.6 1,340 22.3 590 30.7 2,365 21.7 
50-69 years 1,433 48.0 3,296 54.9 1,090 56.6 5,819 53.3 
69-84 years  1,115 37.4 1,371 22.8 245 12.7 2,731 25.0 
Civil status 
single 242 8.1 750 12.5 388 20.2 1,380 12.6 
married 1,766 59.2 3,785 63.0 1,146 59.5 6,697 61.4 
widowed 638 21.4 632 10.5 115 6.0 1,385 12.7 
divorced 337 11.3 840 14.0 276 14.3 1,453 13.3 
Nationality 
Swiss  2,270 76.1 5,455 90.8 1,548 90.8 9,273 85.0 
non-Swiss 713 23.9 552 9.2 377 9.2 1,642 15.0 
Urbanity of residence 
urban 1,225 41.1 2,157 35.9 840 43.6 4,222 38.7 
peri-urban 1,326 44.5 3,417 56.9 1,015 52.7 5,758 52.8 
rural  432 14.5 433 7.2 70 8.6 935 8.6 
Living in an region with organized breast cancer screening 
Yes1 1,457 48.8 1,990 33.1 994 51.6 4,441 40.7 
No2 1,526 51.2 4,017 66.9 931 48.4 6,474 59.3 
         
Total      N     row % 2,983 27.3 6,007 55.0 1,925 17.6 10,915 100.0 
(2) Survival analysis (N=16,296)       
Stage at presentation 
Local 2,507 51.4 4,633 53.4 1,535 56.1 8,675 53.2 
regional 1,778 36.5 3,254 37.5 982 36.0 6,014 36.9 
Distant 267 5.5 396 4.6 110 4.0 773 4.7 
unknown stage 326 6.7 400 4.6 108 4.0 834 5.1 
Age at presentation 
<50 years 608 12.5 1,958 22.6 818 29.9 3,384 20.8 
50-69 years 2,252 46.2 4710 54.2 1,566 57.3 8,528 52.3 
70-84 years  2,018 41.4 2,015 23.2 351 12.8 4,384 26.9 
Civil status 
Single 387 7.9 1,115 12.8 527 19.3 2,029 12.5 
Married 2,838 58.2 5,483 63.2 1,659 60.6 9,980 61.2 
widowed 1,106 22.7 918 10.6 175 6.4 2,199 13.5 
divorced 547 11.2 1,167 13.4 374 13.7 2,088 12.8 
Nationality 
Swiss  3,788 77.7 7,878 90.7 2,211 80.8 13,877 85.2 
non-Swiss 1,090 22.4 805 9.3 524 19.2 2,419 14.8 
Urbanity of residence 
urban 1,852 38.0 2,949 34.0 1,059 38.7 5,860 36.0 
peri-urban 2,088 42.8 4,731 54.5 1,435 52.5 8,254 50.7 
rural  938 19.2 1,003 11.6 241 8.8 2,182 13.4 
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Living in a canton with organized breast cancer screening 
Yes3 2,600 53.3 3,828 44.1 1,588 58.1 8,016 49.2 
No4 2,278 47.7 4,855 55.9 1,147 41.9 8,280 50.8 
         
Vital status at end of follow-up 
Alive 3,277 67.2 6,819 78.5 2,258 82.6 12,354 75.8 
Dead 1,510 31.0 1,780 20.5 423 15.5 3,713 22.8 
lost-to-follow-up 91 1.9 84 1.0 54 2.0 229 1.4 
         
Total      N     row % 4,878 29.9 8,683 53.3 2,735 16.8 16,296 100,0 
 
 
 
 
 
  
Note: For stage analyses, 92 cases (0.8%) out of originally 11,007 cases have been excluded due to missing SEP information. For survival analyses 147 cases (0.9%) out of originally 
16,516 cases have been excluded due to missing SEP information. From the remaining dataset, 73 additional cases were excluded due to zero survival time (death certificate only 
cases or cases first diagnosed at autopsy). 
1Geneva, Valais; 2Zurich; 3Fribourg, Geneva, Valais, Vaud; 4Neuchâtel, Ticino, Zurich. In Neuchâtel, an organized screening programme was implemented in 2007. Incident cases of 
the years 2007 and 2008 were excluded from analyses.  
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Figure 1: Distribution of breast cancer stage at presentation by socioeconomic position (SEP), age-group and canton of 
residence (canton with organized mammography screening: Geneva, Valais; canton without organized mammography 
screening: Zurich). 
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Table 2: Odds ratio (OR) of later stage at breast cancer at presentation: Carcinoma in situ and invasive breast cancer 
cases from three Swiss cancer registries (CRs)  
 
 Model 1 Model 2 Model 3 
 OR [95%CI] OR [95%CI] OR [95%CI] 
       
SEP       
High SEP (ref.)       
Middle SEP 1.18 [1.07-1.31] 1.17 [1.05-1.29] 1.09 [0.99-1.21] 
Low SEP 1.30 [1.16-1.46] 1.25 [1.12-1.41] 1.19 [1.06-1.34] 
       
Age at presentation       
50-69 years (ref.)       
30-49 years   1.24 [1.13-1.36] 1.22 [1.11-1.33] 
70-84 years   1.41 [1.27-1.55] 1.31 [1.19-1.45] 
       
Civil status       
married (ref.)       
single   1.14 [1.01-1.27] 1.13 [1.01-1.27] 
widowed   1.13 [1.00-1.28] 1.12 [0.99-1.27] 
divorced   1.18 [1.06-1.32] 1.14 [1.02-1.27] 
       
Nationality       
Swiss (ref.)       
Non-Swiss   0.97 [0.87-1.07] 0.97 [0.88-1.08] 
       
Urbanity       
urban (ref.)       
peri-urban     0.93 [0.86-1.01] 
rural     0.98 [0.84-1.14] 
       
Organized screening1       
yes (ref.)       
no     1.42 [1.30-1.55] 
Three models have been calculated using the following variables as predictors: (model 1) SEP; (model 2) model 1 plus age at presentation, civil 
status and nationality; (model 3) model 2 plus canton with or without organized screening programme and urbanity of residence. The third model 
has been additionally adjusted for canton of residence. 
1Cantons with organized screening: Geneva, Valais; canton without organized screening: Zurich.  
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Table 3: Subhazard ratios and 95% confidence intervals (95%CI), competing risk survival after breast 
cancer in Swiss women 
 Model 1 Model 2 Model 3 Model 4 
 SHR [95%CI] SHR [95%CI] SHR [95%CI] SHR [95%CI] 
         
SEP         
High SEP (ref.)         
Middle SEP 1.20 [1.06-1.37] 1.13 [0.99-1.29] 1.06 [0.92-1.22] 1.01 [0.88-1.16] 
Low SEP 1.60 [1.40-1.83] 1.39 [1.21-1.61] 1.29 [1.11-1.50] 1.22 [1.05-1.43] 
         
Age at 
presentation 
        
50-69 years 
(ref.) 
        
30-49 years   0.84 [0.74-0.95] 0.77 [0.67-0.87] 0.76 [0.66-0.86] 
70-84 years   1.48 [1.33-1.64] 1.31 [1.17-1.47] 1.34 [1.19.1.50] 
         
Civil status         
married (ref.)         
single   1.24 [1.09-1.42] 1.14 [0.99-1.31] 1.16 [1.00-1.33] 
widowed   1.10 [0.97-1.25] 1.09 [0.95-1.26] 1.09 [0.94-1.26] 
divorced   1.02 [0.89-1.17] 0.94 [0.82-1.09] 0.97 [0.83-1.12] 
         
Nationality         
Swiss (ref.)         
Non-Swiss   0.82 [0.72-0.94] 0.80 [0.69-0.92] 0.84 [0.73-0.98] 
         
Stage at 
presentation 
        
local (ref.)         
regional     4.21 [3.75-4.74] 4.12 [3.66-4.63] 
distant     26.92 [23.39-30.98]] 27.27 [23.67-31.41] 
         
Urbanity         
urban (ref.)         
peri-urban       1.13 [1.02-1.26] 
rural       1.21 [1.03-1.41] 
         
Organized 
screening 
        
yes (ref.)         
no       1.44 [1.23-1.68] 
Survival was analysed using competing risk regressions based on Fine and Gray's proportional hazard model 21. All underlying causes of death 
other than breast cancer were classified as competing risks. Four models have been calculated using the following variables as predictors: (model 
1) SEP; (model 2) model 1 plus age at presentation, civil status and nationality; (model 3) model 2 plus stage at presentation; and (model 4) 
model 3 plus canton with or without organized screening programme and urbanity of residence. The fourth model has been additionally adjusted 
for canton of residence. Results are reported as sub-hazard ratios for breast cancer survival (SHRs) with 95% confidence intervals (95%CI).  
1Cantons with organized screening: Fribourg, Geneva, Valais, Vaud;  cantons without organized screening: Neuchâtel, Ticino, Zurich. In Neuchâtel, 
an organized screening programme was implemented in 2007. Incident cases of the years 2007 and 2008 were excluded from analyses.  
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Suppl. Table 1: Odds ratio (OR) of later breast cancer stage at at presentation: invasive breast cancer cases from seven Swiss 
cancer registries (CRs). 
 Model 1 Model 2 Model 3 
 OR [95%CI] OR [95%CI] OR [95%CI] 
       
SEP       
High SEP (ref.)       
Middle SEP 1.11 [1.01-1.21] 1.11 [1.02-1.22] 1.07 [0.98-1.17] 
Low SEP 1.16 [1.06-1.28] 1.17 [1.06-1.29] 1.15 [1.04-1.27] 
       
Age at presentation       
50-69 years (ref.)       
30-49 years   1.32 [1.22-1.43] 1.31 [1.21-1.42] 
70-84 years   1.20 [1.11-1.30] 1.21 [1.11-1.32] 
       
Civil status       
married (ref.)       
single   1.10 [1.00-1.21] 1.08 [0.98-1.19] 
widowed   1.03 [0.93-1.15] 1.02 [0.92-1.13] 
divorced   1.07 [0.98-1.18] 1.06 [0.97-1.17] 
       
Nationality       
Swiss (ref.)       
Non-Swiss   1.00 [0.91-1.09] 1.01 [0.93-1.11] 
       
Urbanity       
urban (ref.)       
peri-urban     0.95 [0.89-1.02] 
rural     1.06 [0.96-1.19] 
       
Organized screening1       
yes (ref.)       
no     1.45 [1.31-1.60] 
Three models have been calculated using the following variables as predictors: (model 1) SEP; (model 2) model 1 plus age at presentation, civil 
status and nationality; (model 3) model 2 plus canton with or without organized screening programme and urbanity of residence. The third model 
has been additionally adjusted for canton of residence. 
1Cantons with organized screening: Fribourg, Geneva, Valais, Vaud; cantons without organized screening: Neuchâtel, Ticino, Zurich. In Neuchâtel, 
an organized screening programme was implemented in 2007. Incident cases of the years 2007 and 2008 were excluded from analyses 
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Suppl. Table 2: Contribution of carcinoma in situ and invasive breast cancer cases from three Swiss cancer 
registries (CRs) to the pooled dataset to investigate the association between socioeconomic position and 
stage at presentation, incidence period 05/12/2000 - 31/12/2008  
CR 
 
 
All cases 
  Cases with stage 
information 
Cases 
(N) 
% of 
pooled 
dataset 
  
Cases 
(N) 
% of 
pooled 
dataset 
Geneva (a) 2,827 26.0   2,721 26.3 
Valais (a) 1,614 14.8   1,547 14.9 
Zurich (b) 6,474 59.3   6,094 58.8 
Note: 92 cases (0.8%) out of originally 11,007 cases have been excluded due to missing SEP information. 
(a) Canton with organized mammography screening. 
(b) Canton without organized mammography screening. 
 
 
 
Suppl. Table 3: Contribution of invasive breast cancer cases to the pooled dataset from seven Swiss 
cancer registries (CRs) to investigate the association of socioeconomic position and breast cancer survival, 
incidence period 05/12/2000 - 31/12/2008 
CR 
all stages   with stage information  
Cases 
(N) 
Person-years 
(PY) 
% of pooled 
PY 
 
Cases 
(N) 
Person-
years (PY) 
% of 
pooled 
PY 
Fribourg (a, c) 474 2,817 2.2  460 2,737 2.3 
Geneva (a) 2,501 20,488 16.1  2,405 19,877 16.4 
Neuchâtel (b, d) 707 5,871 4.6  620 5,318 4.4 
Ticino (b) 1,773 13,856 10.9  1,712 13,174 10.8 
Valais (a) 1,458 11,410 9.0  1,393 11,022 9.1 
Vaud (a) 3,583 28,378 22.3  3,395 27,312 22.5 
Zurich (b) 5,800 44,220 34.8  5,477 42,113 34.6 
Note: 147 cases (0.9%) out of originally 16,516 cases have been excluded due to missing SEP information. From the 
remaining dataset, 73 additional cases were excluded due zero survival time (death certificate only cases or cases first 
diagnosed at autopsy). 
(a) Canton with organized mammography screening for the time period under investigation. 
(b) Canton without organized mammography screening for the time period under investigation. 
(c) Fribourg contributed cases from 01/01/2006-31/12/2008 only. 
(d) In Neuchâtel, mammography screening was implemented in 2007. Incident cases from the years 2007/2008 were 
excluded from analyses. 
